Literature DB >> 23410062

Dendrimer nanoparticles for ocular drug delivery.

Siva P Kambhampati1, Rangaramanujam M Kannan.   

Abstract

Eye is a unique organ of perfection and complexity, and is a microcosm of the body in many ways. It represents a great opportunity for nanomedicine, since it is readily accessible-allowing for direct drug/gene delivery to maximize the therapeutic effect and minimize side effects. The development of appropriate delivery systems that can sustain and deliver therapeutics to the target tissues is a key challenge that can be addressed by nanotechnology. Dendrimers are tree-like, nanostructured polymers that have received significant attention as ocular drug delivery systems, due to their well-defined size, tailorable structure, and potentially favorable ocular biodistribution. In this review, we highlight recent developments in dendrimer-based ocular therapies for both anterior and posterior segment diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23410062     DOI: 10.1089/jop.2012.0232

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  29 in total

1.  Pediatric ocular nanomedicines: Challenges and opportunities.

Authors:  Natasha D Sheybani; Hu Yang
Journal:  Chin Chem Lett       Date:  2017-07-26       Impact factor: 6.779

2.  Dendrimers for Ocular Drug Delivery.

Authors:  Michael G Lancina; Hu Yang
Journal:  Can J Chem       Date:  2017-05-11       Impact factor: 1.118

Review 3.  Nanocrystal for ocular drug delivery: hope or hype.

Authors:  Om Prakash Sharma; Viral Patel; Tejal Mehta
Journal:  Drug Deliv Transl Res       Date:  2016-08       Impact factor: 4.617

4.  Synthesis and evaluation of a nanoglobular dendrimer 5-aminosalicylic Acid conjugate with a hydrolyzable schiff base spacer for treating retinal degeneration.

Authors:  Xueming Wu; Guanping Yu; Chengcai Luo; Akiko Maeda; Ning Zhang; Da Sun; Zhuxian Zhou; Anthony Puntel; Krzysztof Palczewski; Zheng-Rong Lu
Journal:  ACS Nano       Date:  2013-12-20       Impact factor: 15.881

Review 5.  Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.

Authors:  Abhirup Mandal; Dhananjay Pal; Vibhuti Agrahari; Hoang My Trinh; Mary Joseph; Ashim K Mitra
Journal:  Adv Drug Deliv Rev       Date:  2018-01-13       Impact factor: 15.470

Review 6.  Nanoengineering of therapeutics for retinal vascular disease.

Authors:  Nivriti Gahlaut; Sandra Suarez; Md Imam Uddin; Andrew Y Gordon; Stephanie M Evans; Ashwath Jayagopal
Journal:  Eur J Pharm Biopharm       Date:  2015-05-28       Impact factor: 5.571

7.  Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells.

Authors:  Siva P Kambhampati; Manoj K Mishra; Panagiotis Mastorakos; Yumin Oh; Gerard A Lutty; Rangaramanujam M Kannan
Journal:  Eur J Pharm Biopharm       Date:  2015-02-19       Impact factor: 5.571

Review 8.  Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation.

Authors:  Anil Kumar; Fei Chen; Anbu Mozhi; Xu Zhang; Yuanyuan Zhao; Xiangdong Xue; Yanli Hao; Xiaoning Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanoscale       Date:  2013-09-21       Impact factor: 7.790

9.  Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells.

Authors:  Panagiotis Mastorakos; Siva P Kambhampati; Manoj K Mishra; Tony Wu; Eric Song; Justin Hanes; Rangaramanujam M Kannan
Journal:  Nanoscale       Date:  2015-03-07       Impact factor: 7.790

10.  Subconjunctival dendrimer-drug therapy for the treatment of dry eye in a rabbit model of induced autoimmune dacryoadenitis.

Authors:  Hui Lin; Ying Liu; Siva P Kambhampati; Chih-Chien Hsu; Rangaramanujam M Kannan; Samuel C Yiu
Journal:  Ocul Surf       Date:  2018-05-16       Impact factor: 5.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.